The Yale Center for Asthma and Airway Diseases (YCAAD) is now enrolling patients for a randomized, double-blind, placebo-controlled, parallel group, multicenter Phase 2a Study to explore the efficacy and safety of Tezepelumab (anti-TSLP) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) (COURSE).
Please see the flyer below for all pertinent information.